Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/10863
Title: | SARS CoV subunit vaccine: Antibodymediated neutralisation and enhancement |
Authors: | Jaume, M Yip, MS Kam, YW Cheung, CY Kien, F Roberts, A Li, PH Dutry, I Escriou, N Daeron, M Bruzzone, R Subbarao, K Peiris, JSM Nal, B Altmeyer, R |
Keywords: | SARS-CoV;Vaccine;Antibody;Spike-protein trimers;triSpike;Human haematopoietic cells |
Issue Date: | 2012 |
Citation: | Hong Kong Medical Journal, 2012, 18 (SUPP2), pp. 31 - 36 |
Abstract: | 1. A SARS vaccine was produced based on recombinant native full-length Spike-protein trimers (triSpike) and efficient establishment of a vaccination procedure in rodents. 2. Antibody-mediated enhancement of SARS-CoV infection with anti-SARS-CoV Spike immune-serum was observed in vitro. 3. Antibody-mediated infection of SARS-CoV triggers entry into human haematopoietic cells via an FcγR-dependent and ACE2-, pH-, cysteine-protease-independent pathways. 4. The antibody-mediated enhancement phenomenon is not a mandatory component of the humoral immune response elicited by SARS vaccines, as pure neutralising antibody only could be obtained. 5. Occurrence of immune-mediated enhancement of SARS-CoV infection raises safety concerns regarding the use of SARS-CoV vaccine in humans and enables new ways to investigate SARS pathogenesis (tropism and immune response deregulation). |
URI: | http://bura.brunel.ac.uk/handle/2438/10863 |
ISSN: | 1024-2708 |
Appears in Collections: | Dept of Electronic and Electrical Engineering Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | 431.56 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.